Millennium/EntreMed Show Opposite Ends Of Biotech Hype Cycle
Executive Summary
Wall Street's muted reaction to Millennium's recent announcements of progress in understanding the genetic basis of obesity illustrates the fickle nature of hype involving biotechnology research.
You may also be interested in...
OSI Endorses Apoptosis; Cell Pathways Deal Brings Two Clinical Candidates
OSI Pharmaceuticals is investing in a second oncologic research pathway via the proposed acquisition of Cell Pathways for $32 mil
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011